



**TRANSMITTAL LETTER  
(General - Patent Pending)**

Docket No.  
3829.02-1

In re: Application Of: **WILLIAM J. WECHTER**

Serial No.  
10/734,687

Filing Date  
DECEMBER 11, 2003

Examiner  
N/A

Group Art Unit  
N/A

Title: **METHODS FOR SCREENING COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE**

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

1. TRANSMITTAL LETTER;
2. TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT;
3. PTO FORM 1449;
4. COPIES OF REFERENCES A-U); AND
5. POSTCARD.

in the above identified application.

- ☐ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **16-1331** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

  
Signature

Dated: **MARCH 15, 2004**

**HANA VERNY (REG. NO. 30,518)  
PETERS, VERNY, JONES & SCHMITT, L.L.P  
425 SHERMAN AVENUE, SUITE 230  
PALO ALTO, CA 94306  
TEL: (650)324-1677  
FAX: (650)324-1678**

I certify that this document and fee is being deposited  
**MARCH 15, 2004** with the U.S. Postal Service as  
first class mail under 37 C.F.R. 1.8 and is addressed to the  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA  
22313-1450.

  
Signature of Person Mailing Correspondence

**MELINDA TOMPKINS**

Typed or Printed Name of Person Mailing Correspondence

cc:

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT****(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.

3829.02-1

In Re Application Of: **WECHTER**

Serial No.

10/734,687

Filing Date

DECEMBER 11, 2003

Examiner

N/A

Group Art Unit

N/A

Title: **METHODS FOR SCREENING COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE**

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.  
3829.02-1In Re Application: **WECHTER**

Serial No.

10/734,687

Filing Date

DECEMBER 11, 2003

Examiner

N/A

Group Art Unit

N/A

**METHODS FOR SCREENING COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **16-1331** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**I certify that this document and fee is being deposited on **MARCH 15, 2004** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

MELINDA TOMPKINS

Typed or Printed Name of Person Mailing Certificate

**\*This certificate may only be used if paying by deposit account.**

Signature

**HANA VERNY (REG. NO. 30,518)**  
**PETERS, VERNY, JONES & SCHMITT, L.L.P.**  
**425 SHERMAN AVENUE, SUITE 230**  
**PALO ALTO, CA 94306**  
**TEL: (650)324-1677**  
**FAX: (650)324-1678**

Dated: **MARCH 15, 2004**

CC:

# LIST OF PATENTS AND PUBLICATIONS FOR APPLICANTS INFORMATION DISCLOSURE STATEMENT

**ATTY. DOCKET NO.**

SERIAL NO.

**3829.02-1**

10/734.687

**APPLICANT : WECHTER**

**FILING DATE : DECEMBER 11, 2003**

**GROUP** N/A

REFERENCE DESIGNATION	U.S. PATENT DOCUMENTS
1	2,811,311
2	2,811,312
3	2,811,313
4	2,811,314
5	2,811,315
6	2,811,316
7	2,811,317
8	2,811,318
9	2,811,319
10	2,811,320
11	2,811,321
12	2,811,322
13	2,811,323
14	2,811,324
15	2,811,325
16	2,811,326
17	2,811,327
18	2,811,328
19	2,811,329
20	2,811,330
21	2,811,331
22	2,811,332
23	2,811,333
24	2,811,334
25	2,811,335
26	2,811,336
27	2,811,337
28	2,811,338
29	2,811,339
30	2,811,340
31	2,811,341
32	2,811,342
33	2,811,343
34	2,811,344
35	2,811,345
36	2,811,346
37	2,811,347
38	2,811,348
39	2,811,349
40	2,811,350
41	2,811,351
42	2,811,352
43	2,811,353
44	2,811,354
45	2,811,355
46	2,811,356
47	2,811,357
48	2,811,358
49	2,811,359
50	2,811,360
51	2,811,361
52	2,811,362
53	2,811,363
54	2,811,364
55	2,811,365
56	2,811,366
57	2,811,367
58	2,811,368
59	2,811,369
60	2,811,370
61	2,811,371
62	2,811,372
63	2,811,373
64	2,811,374
65	2,811,375
66	2,811,376
67	2,811,377
68	2,811,378
69	2,811,379
70	2,811,380
71	2,811,381
72	2,811,382
73	2,811,383
74	2,811,384
75	2,811,385
76	2,811,386
77	2,811,387
78	2,811,388
79	2,811,389
80	2,811,390
81	2,811,391
82	2,811,392
83	2,811,393
84	2,811,394
85	2,811,395
86	2,811,396
87	2,811,397
88	2,811,398
89	2,811,399
90	2,811,400
91	2,811,401
92	2,811,402
93	2,811,403
94	2,811,404
95	2,811,405
96	2,811,406
97	2,811,407
98	2,811,408
99	2,811,409
100	2,811,410
101	2,811,411
102	2,811,412
103	2,811,413
104	2,811,414
105	2,811,415
106	2,811,416
107	2,811,417
108	2,811,418
109	2,811,419
110	2,811,420
111	2,811,421
112	2,811,422
113	2,811,423
114	2,811,424
115	2,811,425
116	2,811,426
117	2,811,427
118	2,811,428
119	2,811,429
120	2,811,430
121	2,811,431
122	2,811,432
123	2,811,433
124	2,811,434
125	2,811,435
126	2,811,436
127	2,811,437
128	2,811,438
129	2,811,439
130	2,811,440
131	2,811,441
132	2,811,442
133	2,811,443
134	2,811,444

**EXAMINER  
INITIAL**

INITIAL

**DOCUMENT NUMBER**

DATE \_\_\_\_\_

NAME \_\_\_\_\_

CLAS

SUBCLASS

FILING DATE  
IF APPROPRIATE

DOCUMENT NUMBER

DATE \_\_\_\_\_

COUNTRY

CLAS

SUBCLASS

TRANSLATION	
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

**YES**

**NO**

US

## OTHER

**ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

A	Romualda D. Knihinicki, et al., Chiral Inversion of 2-Arylpropionic Acid Non-Steroidal Anti-Inflammatory Drugs - II, <u>Biochemical Pharmacology</u> , 42/10: 1905-1911 (1991).
B	S. Ferdinandusse, et al., Stereochemistry of the Peroxisomal Branched-Chain Fatty Acid Alpha- and Beta-Oxidation Systems in Patients Suffering From Different Peroxisomal Disorders, <u>Journal of Lipid Research</u> , 43:438-444 (2002).
C	Christine Reichel, et al., 2-Arylpropionyl-CoA Epimerase: Partial Peptide Sequences and Tissue Localization, <u>Biochemical Pharmacology</u> , 50/11:1803-1806 (1995).
D	Timothy S. Tracy, et al., Metabolic Inversion of (R)-Ibuprofen, Formation of Ibuprofenyl-Coenzyme A, <u>Drug Metabolism and Disposition</u> , 21/1: 114-120 (1993).
E	Christine Reichel, et al., Molecular Cloning and Expression of a 2-Arylpropionyl-Coenzyme A Epimerase: A Key Enzyme in the Inversion Metabolism of Ibuprofen, <u>Molecular Pharmacology</u> , 51:576-582 (1997).
F	Ching-Shih Chen, et al., Metabolic Stereoisomeric Inversion of Ibuprofen in Mammals, <u>Biochemica et Biophysica Acta</u> 1078:411-417 (1991).
G	Tiina J. Kotti, et al., In Mouse Alpha-Methylacyl-CoA Racemase, the Same Gene Product is Simultaneously Located in Mitochondria and Peroxisomes, <u>The Journal of Biochemical Chemistry</u> , 275/27:20887-20895 (2000).
H	Woan-Ru Shieh, et al., Purification and Characterization of Novel "2-Arylpropionyl-CoA Epimerases" From Rat Liver Cytosol and Mitochondria, <u>The Journal of Biological Chemistry</u> , 268/5:3487-3493 (1993).
I	Leen Amery, et al., Mitochondrial and Peroxisomal Targeting of 2-Methylacyl-CoA Racemase in Humans, <u>Journal of Lipid Research</u> , 41:1752-1759 (2000).
J	Jun Luo, et al., Alpha-Methylacyl-CoA Racemase: A New Molecular Marker for Prostate Cancer, <u>Cancer Research</u> , 62:2220-2226 (April 15, 2002).
K	Rainer Kuefer, et al., Alpha-Methylacyl-CoA Racemase: Expression Levels of This Novel Cancer Biomarker Depend on Tumor Differentiation, <u>American Journal of Pathology</u> , 161/3:841-848 (September 2002).
L	Mark A. Rubin, et al., Alpha-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer, <u>JAMA</u> , 287/13:1662-1670 (April 3, 2002).
M	Zhong Jiang, et al., P504S/Alpha-Methylacyl-CoA Racemase, A Useful Marker for Diagnosis of Small Foci of Prostatic Carcinoma on Needle Biopsy, <u>The American Journal of Surgical Pathology</u> , 26/9:1169-1174 (2002).
N	Jiangchun Xu, et al., Identification of Differentially Expressed Genes in Human Prostate Cancer Using Subtraction and Microarray, <u>Cancer Research</u> , 60:1677-1682 (March 15, 2000).
O	Zhong Jiang, et al., P504S, A New Molecular Marker for the Detection of Prostate Carcinoma, <u>The American Journal of Surgical Pathology</u> , 25/11:1397-1404 (2001).
P	Ximing J. Yang, et al., Expression of Alpha-Methylacyl-CoA Racemase (P504S) in Atypical Adenomatous Hyperplasia of the Prostate, <u>The American Journal of Surgical Pathology</u> , 26/7:921-925 (2002).
Q	Diquan L. Zheng, et al., Sequence Variants of Alpha-Methylacyl-CoA Racemase Are Associated with Prostate Cancer Risk, <u>Cancer Research</u> , 62:6485-6488 (November 15, 2002).
R	Sacha Ferdinandusse, et al., Subcellular Localization and Physiological Role of Alpha-Methylacyl-CoA Racemase, <u>Journal of Lipid Research</u> , 41:1890-1896 (2000).
S	Werner Schmitz, et al., Molecular Cloning of cDNA Species for Rat and Mouse Liver Alpha-Methylacyl-CoA Racemases, <u>Biochem. J.</u> , 326:883-889 (1997).

		T	Ming Zhou, et al., Alpha-Methylacyl-CoA-Racemase, A Novel Tumor Marker Over-Expressed in Several Human Cancers and Their Precursor Lesions, <i>The American Journal of Surgical Pathology</i> , 26/7:926-931 (2002).
		U	Sacha Ferdinanusse, et al., Plasma Analysis of Di- and Trihydroxycholestanoic Acid Diastereoisomers in Peroxisomal Alpha-Methylacyl-CoA Racemase Deficiency, <i>Journal of Lipid Research</i> , 42:137-141 (2001).

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.